Anzeige
Mehr »
Montag, 02.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
83 Leser
Artikel bewerten:
(0)

Acquisition of stake in Famdent

1 March 2011

UBM agrees to acquire stake in Famdent, India's largest dental exhibition and 
conference business

Expands UBM Medica's Indian event portfolio into the dental sector

United Business Media Limited today announces that it has agreed to form a
joint venture with Drs Anil and Jyotika Arora to operate the Famdent dental
exhibition and conference business in India. UBM will own 60% of the Famdent
business, with the remainder of the business being owned by Drs Anil and
Jyotika Arora. The transaction is expected to complete in the next three
months. UBM is forming the joint venture on behalf of its UBM Medica business.

Established 11 years ago, Famdent (www.famdent.com) launched its first event
for the professional dentistry community in Mumbai in 2005, adding its Delhi
event in 2009. The shows combine exhibition and conference elements, between
them attracting more than 120 exhibitors, 2,200 conference delegates and 3,300
exhibition visitors. The success of Famdent's events reflects the rapid
expansion of the Indian dentistry profession, estimated to be a $120 million
industry and growing 15-20% annually. There are more than 100,000 qualified
dentists currently practising in India, with around 13,000 new dentists
entering the market each year from 191 dental colleges. India's major cities
now have approximately 12,000 dental clinics.

Famdent's events are supported by an eponymous clinical dental publication
which has a controlled circulation of up to 12,000 copies per quarter. The
publication contributed around 30% of the business' revenues in 2010.

Famdent's founders, Drs Anil and Jyotika Arora, will remain with the business
following the formation of the joint venture, together with a further 13
employees. For the year ended 31 March 2010, the business generated revenues of
approximately £0.4 million. Its gross assets were £0.3m.

UBM's investment in the joint venure is anticipated to provide a return in
excess of UBM's cost of capital criterion in its first full year of operation.

Henry Elkington, Chief Executive of UBM Medica said:

"The creation of our Famdent joint venture brings us a leading position in
India's rapidly-growing dental industry. I look forward to working with Anil
and Jyotika Arora to grow the Famdent shows and to extend them to new
territories across India and Asia. With our expanded platform in this space, we
will also seek to broaden our offering in other Indian medical exhibition and
conference markets."

                                   - Ends -                                    

Contacts

Media                                                              
                                                                   
Peter Bancroft             Director of Communications              
                                                                   
E-mail                     communications@ubm.com                  
                                                                   
Direct telephone           +44 20 7921 5961
                        
                                                                   
Chris Barrie               Citigate Dewe Rogerson                  
                                                                   
E-mail                     chris.barrie@citigatedr.co.uk           
                                                                   
Direct telephone           +44 20 7282 2943                        
                                                                   
Mobile                     +44 796 872 72 89 
                      
                                                                   
Analysts/Investors                                                 
                                                                   
Kate Postans               Head of Investor Relations              
                                                                   
Email                      investorrelations@ubm.com               
                                                                   
Direct telephone           +44 20 7921 5095                        
                                                                   

Notes to Editors

1. About UBM

UBM focuses on two principal activities: worldwide information distribution,
targeting and monitoring; and the development and monetisation of B2B
communities and markets. UBM's businesses inform markets and serve professional
commercial communities - from doctors to game developers, from journalists to
jewellery traders, from farmers to pharmacists - with integrated events,
online, print and business information products. Our 5,900 staff in more than
30 countries are organised into specialist teams that serve these communities,
bringing buyers and sellers together, helping them to do business and their
markets to work effectively and efficiently.

For more information, go to www.ubm.com

2. About UBM Medica

UBM Medica is a leading healthcare media company providing bespoke solutions to
a global healthcare market. We provide reference data, decision support
solutions, news and education to communities of general practitioners,
specialist doctors, pharmacists, nurses and patients across 26 countries.  We
produce a range of professional media including data-rich directories,
electronic and online products, journals and face-to-face meetings. The
established and trusted reputation of our brands means that many of them are
embedded in the daily workflow of the healthcare communities they serve.

For more information, go to www.ubmedica.com



END

UNITED BUSINESS MEDIA LIMITED

© 2011 PR Newswire
Tech-Aktien schwanken – 3 Versorger mit Rückenwind
Die Stimmung an den Märkten hat sich grundlegend gedreht. Während Tech- und KI-Werte zunehmend mit Volatilität und Bewertungsrisiken kämpfen, erleben klassische Versorger ein unerwartetes Comeback. Laut IEA und EIA steigt der globale Strombedarf strukturell weiter, nicht nur wegen E-Mobilität und Wärmepumpen, sondern vor allem durch energiehungrige KI-Rechenzentren. Energie wird damit zur zentralen Infrastruktur des digitalen Zeitalters.

Gleichzeitig rücken in unsicheren Marktphasen stabile Cashflows, solide Bilanzen und regulierte Renditen wieder stärker in den Fokus. Genau hier spielen Versorger ihre Stärken aus: berechenbare Erträge, robuste Nachfrage und hohe Dividenden – Qualitäten, die vielen Wachstumswerten aktuell fehlen.

Nach Jahren im Schatten der Tech-Rallye steigt nun das Interesse an Unternehmen, die Stabilität mit langfristigen Wachstumsthemen wie Netzausbau, Dekarbonisierung und erneuerbaren Energien verbinden.

Im aktuellen Spezialreport stellen wir drei Versorger vor, die defensive Stärke mit attraktivem Potenzial kombinieren.

Jetzt den kostenlosen Report sichern – bevor die nächste Versorgerwelle Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.